Latest Conference Coverage
Future Plans and Clinical Promise of Inebilizumab in Myasthenia Gravis: Richard Nowak, MD, MS
October 25th 2024The director of the myasthenia gravis clinic at Yale University provided additional insight on the MINT study of inebilizumab in myasthenia gravis, some of the subanalyses within, and next plans in the drug’s development. [WATCH TIME: 5 minutes]
The Potential of Device-Assisted Therapies in PD: Insights From the Phase 1/2 DIVE-I Trial
October 25th 2024David Devos, MD, PhD, a neuropharmacologist at the University of Lille, in France, discussed positive data from an early-stage study assessing InBrain Pharma’s device-assisted therapy in Parkinson disease.
Challenges and Opportunities of Adapting Medical Education in a Digital Age: Lawrence Robinson, MD
October 24th 2024The senior scientist at Sunnybrook Research Institute talked about both the opportunities and challenges with the shift of technological advancement in medical education, especially in fostering critical thinking and managing the vast influx of information. [WATCH TIME: 4 minutes]
Revised McDonald Diagnostic Criteria Signals New Era in Multiple Sclerosis Treatment
October 22nd 2024The 2024 revisions to the McDonald diagnostic criteria for multiple sclerosis (MS) mark a significant advancement in the early detection and diagnosis of the disease, with new biomarkers and a broadened scope that may lead to earlier intervention and improved patient outcomes.
Understanding Nipocalimab’s Impact on Myasthenia Gravis Using MG-ADL
October 22nd 2024Constantine Farmakidis, MD, an associate professor of neurology at the University of Kansas Medical Center, provided clinical commentary on a subanalysis of a phase 3 study assessing nipocalimab, an investigational agent, in generalized myasthenia gravis.
Details Behind the Phase 3 MyClad Study of Cladribine in Myasthenia Gravis
October 22nd 2024Study investigator Henry Kaminski, MD, provided clinical insight on a unique trial assessing the efficacy and safety of oral cladribine tablets, an FDA-approved medication for multiple sclerosis, in patients with myasthenia gravis.
Phase 3 Trial to Assess Therapeutic Effect of IV Efgartigimod in Seronegative Myasthenia Gravis
October 19th 2024The phase 3 study is expected to include 110 patients with seronegative myasthenia gravis who will be randomly assigned to IV efgartigimod or placebo for a 5-week follow-up, followed by an open-label extension.
Phase 3 PREVAIL Study to Test Bispecific Nanoantibody Gefurulimab in Generalized Myasthenia Gravis
October 17th 2024The PREVAIL trial, presented at the 2024 AANEM meeting, is investigating gefurulimab, a bispecific nanoantibody designed to inhibit complement activation, as a potential treatment for patients with generalized myasthenia gravis.
Phase 3 NIMBLE Trial to Test Effects of Pozelimab and Cemdisiran in Myasthenia Gravis
October 16th 2024Pozelimab and cemdisiran work together to block the complement pathway, which plays a key role in gMG, using two different approaches—one suppresses liver production of a key protein, while the other targets it directly with antibodies.
Understanding the Therapeutic Potential of Inebilizumab in Myasthenia Gravis: Richard Nowak, MD, MS
October 16th 2024The director of the myasthenia gravis clinic at Yale University provided clinical insight on promising phase 3 data assessing inebilizumab, an FDA-approved therapy for NMOSD, in patients with myasthenia gravis. [WATCH TIME: 4 minutes]
Understanding the Therapeutic Potential of GT-02287 in GBA-Parkinson Disease
October 14th 2024Jonas Hannestad, MD, PhD, chief medical officer at Gain Therapeutics, provided clinical perspective on promising data from a phase 1 first-in-human study of GT-02287, an investigational therapy for Parkinson disease with or without a GBA1 mutation.
